Boundless Bio, a clinical-stage oncology company, announced its financial results for the first quarter of 2025, highlighting its ongoing commitments to developing innovative therapies for patients ...
Boundless Bio has announced a strategic portfolio prioritization aimed at optimizing its oncology programs, particularly focusing on the combination therapy of BBI-355 and BBI-825, alongside a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results